Kenneth Stark is a Rheumatology/Immunology physician. OpenAlex indexes 25 publications with 1,059 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1613 Banning Beach Rd
Tavares, FL 327782024
Telephone
352-343-7735Registry record last updated 9 Oct 2012.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202537 payments$16,385openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202526 payments$16,363openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202561 payments$15,359openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
71.2%TNF inhibitor57.7%Certolizumab pegol77%Golimumab18%Infliximab5%Humira(Cf) Pen0%Enbrel Sureclick0%Enbrel0%Humira(Cf)0%Cimzia (2 Pack)0%Part D + Part B<11 patientsSelective T Cell Costimulation Modulator13%Abatacept100%Part B, office-administered≥33 patients+ 6 more classes in this area
Musculoskeletal
25.6%RANK Ligand Inhibitor15.5%Denosumab100%Part B, office-administered≥207 patientsOther drugs affecting bone structure and mineralization10%Romosozumab-aqqg100%Part B, office-administered≥14 patients+ 3 more classes in this area
Dermatology
2.5%Corticosteroid2.5%Methylprednisolone acetate99%Methylprednisolone1%Part D + Part B≥53 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Services to Patients with Dual Diagnoses: Findings from Washington's Mental Health Service System
Substance Use & Misuse
2007 - Treatment response by primary drug of abuse: Does methamphetamine make a difference?
Journal of Substance Abuse Treatment
2006 - Substance Abuse Treatment and Criminal Justice Involvement for SSI Recipients: Results from Washington State
American Journal on Addictions
2006
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”